AGY.L StockTwits Mentions

Track AGY.L's AI-powered predictions, market trends, and investment insights.

AGY.L AI Prediction AGY.L Sentiment AGY.L Reddit

Mock Tradesimulated, no real money

You don't hold AGY.L in your mock portfolio yet.

AGY.L StockTwits Mentions

Track AGY.L's AI-powered predictions, market trends, and investment insights.

AGY.L AI Prediction AGY.L Sentiment AGY.L Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-1.3%

Price (7d)-7.1%

Volume vs avg0.7x

Volatility vs normal1.0x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

No flags triggered by these checks.

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~$7.90 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

AGY.L AI Stock Analysis

Financial Performance

bearish

Allergy Therapeutics is currently loss-making, as indicated by its negative EPS and negative P/E ratio. The lack of positive earnings suggests that profitability remains a key challenge, and there is no evidence from the provided data that margins or net income are improving. Until the company can demonstrate a path to sustainable profits, the financial profile appears weak from an equity investor’s standpoint.

Negative EPS of -0.01 indicates the company is not currently profitable on a per-share basis.
A negative P/E ratio (-8.48) confirms loss-making status and limits the usefulness of traditional valuation comparisons.
Without signs of improving earnings or margins, the risk profile remains elevated and the equity story hinges on future turnaround rather than current financial strength.

Stock Price & Technicals

bearish

The stock is trading at $8.48, notably below its 200-day moving average of $10.01, which is a bearish technical signal. A 15% decline over the last month points to recent negative momentum and potential investor concern. While a deeply sold-off stock can sometimes present value, the current setup leans more toward a downtrend than a constructive base.

Current price of $8.48 is materially below the 200-day moving average of $10.01, indicating a sustained downtrend.
The stock has fallen 15.0% in the last month, reflecting strong negative short-term momentum.
With price below a key long-term moving average and no offsetting positive earnings story, technicals currently favor a cautious or defensive stance.

Alternative Data Signals

neutral

Alternative data show a very small direct digital footprint, with low web traffic and minimal social media followings on consumer-facing platforms. LinkedIn presence is comparatively stronger, suggesting some professional and B2B engagement, which is consistent with a specialized healthcare or biotech company. Overall, these signals are not strongly positive or negative for the stock, but they do not provide evidence of growing commercial traction with end customers.

Estimated web traffic of 1,519 visitors per month is modest, implying limited online reach or patient-facing engagement.
Instagram (75 followers) and YouTube (26 subscribers) have shown 0.0% growth over the last 90 days, suggesting stagnant consumer-facing digital engagement.
LinkedIn following of 12,086 indicates a more established professional presence, but this alone does not translate into clear revenue or earnings momentum.

Conclusion

bearish

Overall, the combination of negative earnings, a stock price trending below its long-term moving average, and recent price weakness points to a bearish setup for Allergy Therapeutics. Alternative data do not show clear signs of accelerating commercial traction that might offset the weak financial and technical picture. Until there is evidence of improving profitability or a clear positive catalyst, the risk/reward profile appears skewed to the downside.

Loss-making fundamentals and a negative P/E, combined with a price below the 200-day moving average and a 15% monthly decline, support a bearish view.
Alternative data are largely neutral and do not currently provide a strong counter-signal to the negative financial and technical trends.

AI Score

Hold

Alternative7

Fundamental1

Technical5

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold AGY.L in your mock portfolio yet.